Iovance Biotherapeutics (NASDAQ: IOVA) reported Q4 EPS of ($0.18), $0.01 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $86.71 million versus the consensus estimate of $82.03 million.

For earnings history and earnings-related data on Iovance Biotherapeutics (IOVA) click here.